Study of Frequency Distribution of HbA1c≥6.5 Percent in Patients with Acute Coronary Syndrome in 5Azar Medical and Education Center of Gorgan in 2020

Received 09 Jan, 2024

Accepted 11 Nov, 2024

Published 01 Jan, 2025

Background and Objective: Diabetes is an important public health challenge associated with cardiovascular complications and mortality. The European Society of Cardiology recommends that all patients admitted with acute coronary syndrome (ACS) be screened for diabetes and has recently recommended the use of glycosylated hemoglobin type A1c (HbA1c) as a screening tool in accordance with the World Health Organization.The aim of this study was to determine the frequency distribution of HbA1c above 6.5% as an indicator in the diagnosis of diabetes in patients with acute coronary syndrome.

Methodology: This descriptive study was performed on 77 patients admitted to 5Azar Hospital in Gorgan due to ACS. Patients were studied for demographic and clinical characteristics, as well as laboratory parameters including blood glucose on admission and during hospitalization, HbA1c, cardiac troponin Creatine Kinase MB (ckMB). Data were analyzed using SPSS v.18 software using the Chi-square test.

Results: Most patients were male (58.4%), had no drug and cigarette abuse (76.6%) had no family history of the disease (59.7%). The 54.55% of the studied patients had HbA1c≥6.5% (54.55%). None of the clinical, demographic laboratory indices differed among patients based on the distribution of HbA1c≥6.5% (p<0.05).

Conclusion: Considering that more than half of the patients with ACS in this study had HbA1c in diabetics level but without a history of diabetes, it seems that a significant percentage of patients with ACS become aware of their diabetes for the first time at the time of admission due to acute cardiac symptoms.

KEY CONTRIBUTIONS

The presence of cardiovascular risk factors even without a history of diabetes alarms about HbA1c screening.

FUTURE DIRECTIONS

It is suggested to evaluate and compare the two-year, three-year five-year outcomes of patients with ACS based on the HbA1c cut-off.

ACKNOWLEDGMENT

We hereby thank the participants in the study and also we thank the research ethics committee of Golestan University of Medical Sciences.